Overview

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Status:
Enrolling by invitation
Trial end date:
2024-06-10
Target enrollment:
Participant gender:
Summary
This study is an open label extension study, which means that the participants from the Lead-in Study 19140A (NCT04921384) can join this study, if they meet the study Eligibility Criteria, and continue to receive the study drug eptinezumab. The main goal of this study is to investigate long-term safety and tolerability of eptinezumab in Japanese migraine participants.
Phase:
Phase 3
Details
Lead Sponsor:
H. Lundbeck A/S